Today: 10 July 2026
Browse Category

Pharmaceuticals 10 June 2026 - 24 June 2026

AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie said Monday it’s buying Apogee Therapeutics for $10.9 billion in cash, making this its largest deal since 2019. The company is looking to strengthen its immunology pipeline with Apogee’s long-acting immune-disease drugs. AbbVie and Apogee put out a joint release on the agreement, according to a securities filing. They expect the deal to close in the third quarter of 2026.
22 June 2026
··
Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms

Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms

Outlook Therapeutics, Inc. stock surged Tuesday after the company said the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application, or BLA, for ONS-5010/LYTENAVA as a treatment for wet age-related macular degeneration. A BLA is the FDA application used to seek approval to market a biologic medicine. OTLK traded at $1.51, up about 30.2% from its previous close of $1.16, with intraday volume above 33.7 million shares, according to market data available in afternoon trading.
16 June 2026
··
CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Inc. shares spiked in premarket trading Tuesday, quoted around $3.30 after closing at $2.48 on Monday. The stock was up more than 30%, with MarketScreener and MT Newswires tying the jump to an SEC filing late Monday. The pop wasn’t about new clinical news. Instead, it followed a show of insider confidence: a Form 4 showed the Joshua S. Boger 2021 Trust bought 955,414 units at $3.14 apiece in a private placement, totaling about $3 million. Private placements are limited sales to select investors, not the public.
16 June 2026
··
1 2 3 4 … 43

Stock Market Today

  • Penguin Solutions (PENG) Rolls Out Sept. 2027 Options With Rich Premiums
    July 10, 2026, 11:09 AM EDT. Penguin Solutions Inc. (PENG) rolled out new options expiring September 2027, giving traders 434 days until these contracts end. The $75 put is quoted at a $28.50 bid, letting sellers get in at a roughly 1% discount to PENG's $75.84 share price, and pocket up to a 38% return if the put finishes worthless-a setup seen as 74% probable based on current data. On the upside, the $90 call trades at $29 bid. Writing that covered call now could lock in close to a 57% return if shares are called away. These long-term premiums could appeal to investors searching for yield or aiming to lower cost with puts and boost returns with calls.
Go toTop